article · World Journal of Virology
A systematic review and meta-analysis of 32 studies covering 46,890 patients evaluated the uptake of lumbar puncture procedures among individuals with advanced HIV disease who tested positive for serum cryptococcal antigen. Overall, 5.8% of screened patients were positive for the antigen. Among this group, the pooled uptake of lumbar punctures was 67.7%, dropping to 54.5% when studies reporting complete uptake were excluded. Multicentre studies showed significantly lower procedure uptake compared to single-centre studies. Furthermore, the overall prevalence of cryptococcal meningitis among tested patients was 54.3%, and overall mortality was 6.2%. Patients who tested positive for the serum antigen experienced double the mortality risk of those who tested negative. Gaps in procedure uptake were linked to provider capacity limitations and patient refusals, highlighting the need for clinician training and patient counselling.
Cryptococcal meningitis is a serious complication for individuals living with advanced HIV. Although guidelines recommend lumbar punctures to diagnose the condition accurately and avoid ineffective preventative treatment, up to nearly half of eligible patients do not receive the procedure. Addressing this gap through healthcare training and improved patient counselling is vital to ensuring correct treatment and lowering patient mortality.
The abstract outlines epidemiological and clinical service delivery findings rather than a commercial technology. It identifies practical needs for healthcare provider training programmes and patient counselling interventions to increase lumbar puncture uptake in clinical settings. The abstract does not indicate a commercialisation pathway or direct technology transfer application.
AI-generated from the published abstract. Always read the original work before citing.
BACKGROUND The World Health Organization (WHO) recommends lumbar puncture (LP) procedures to assess the diagnosis of cryptococcal meningitis (CM) among patients with advanced human immunodeficiency virus (HIV) disease (AHD) with positive serum cryptococcal antigen (CrAg) and do not have evidence of CM. AIM To estimate pooled prevalence of uptake of LP, CM and mortality among patients with AHD. METHODS PubMed, Cochrane Library and EMBASE were searched for articles published between January 2011 and December 2024. LP uptake was defined as percentage of people who underwent LP procedures among those with AHD (CD4 ≤ 200 cells/mm3 or WHO stage III/IV) and positive serum CrAg. Using random effects models, we computed the pooled estimate of LP uptake, CM and mortality and 95%CI. Stratified analyses were used to compare uptake of LP between studies that involved multiple vs single sites, and mortality analyses between patients with positive and negative serum CrAg were performed. Sensitivity analysis on LP uptake was done by excluding prospective cohort studies that reported 100% uptake. RESULTS A total of 32 studies with 46890 people with AHD screened for serum CrAg and 2730 (5.8%) had positive serum CrAg. Overall, pooled prevalence of LP uptake was 67.7% (95%CI: 54.0–81.5). The overall pooled prevalence of CM was 54.3% (95%CI: 39.7–69.0), and mortality was 6.2% (95% CI: 4.5–8.0). There is disparities in the pooled prevalence of LP uptake with studies involving multiple sites having lower prevalence compared to those that involved single sites (54.8% vs 84.7%, P = 0.004). By excluding prospective cohort studies that reported 100% uptake, the overall LP uptake was 54.5% (95%CI: 38.8–70.1). The pooled prevalence of CM was significantly lower among studies that involved multiple sites compared to those that involved single sites (6.8% vs 8.1%, P ≤ 0.001). Mortality was significantly twice as high among patients who had positive serum CrAg compared to those who had negative serum CrAg [risk ratio = 2.0 (95%CI: 1.6–2.5), P ≤ 0.001]. CONCLUSION Nearly three to five in 10 people with AHD with positive serum CrAg did not have LP procedures done, indicating significant gaps in identifying patients with CM. Establishing a confirmed diagnosis of CM is critical to avoid exposing patients to subtherapeutic levels of antifungals preemptively. Capacity to perform LP and patient refusals are among the reasons for not performing the procedure. Capacity building in training health care providers to perform LP procedures and professional counselling to obtain patient consent are critical for appropriate treatment to reduce mortality associated with CM infection.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.5501/wjv.v14.i2.106973
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
